New hope for rare thyroid cancer: targeted drug shows promise
NCT ID NCT02657551
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tests a targeted drug called regorafenib in people with a rare type of advanced thyroid cancer (medullary thyroid cancer) that has spread. The goal is to see if the drug can stop or slow cancer growth. Eight adults whose cancer worsened after prior treatments took part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States
Conditions
Explore the condition pages connected to this study.